Common Nasal Spray Shows Promise in Reducing COVID-19 Infection Risk
A clinical study shows that a common antihistamine nasal spray with azelastine can cut COVID-19 infection risk by nearly two-thirds, offering a promising preventive tool against the virus.
A recent clinical study conducted by researchers at Saarland University has revealed that a widely used antihistamine nasal spray, containing azelastine, may significantly lower the risk of contracting COVID-19. The placebo-controlled trial involved 450 healthy volunteers over a 56-day period and demonstrated encouraging results in preventing SARS-CoV-2 infections.
Led by Professor Robert Bals, the study divided participants into two groups: one used the azelastine nasal spray three times daily, while the control group received a placebo spray at the same frequency. Findings showed that only 2.2% of those using the azelastine spray tested positive for COVID-19, compared to 6.7% in the placebo group, representing a reduction of about two-thirds.
In addition to decreasing COVID-19 infections, the azelastine group experienced fewer cases of respiratory illnesses overall. Interestingly, the study also noted a lower incidence of rhinovirus infections, which are a common cause of respiratory cold symptoms, suggesting potential broader antiviral effects.
Azelastine nasal spray has been a staple in allergy treatments for decades and was previously suggested to have antiviral properties based on laboratory studies. This clinical trial marks the first evidence of its protective effects in real-world conditions, according to Professor Bals.
The results hint at practical applications, especially for vulnerable populations or during peak infection periods. The spray could serve as an accessible prophylactic tool alongside existing protective measures like vaccination and mask-wearing. However, Professor Bals emphasized the need for larger, multicenter studies to further explore its preventive potential against COVID-19 and other respiratory viruses.
Funding for the research was provided by Saarbrücken-based pharmaceutical company URSAPHARM Arzneimittel GmbH, which also manufactured the nasal spray used in the trial.
This development offers a promising step toward additional preventive options in managing viral respiratory infections, complementing current public health strategies.
source: https://medicalxpress.com/news/2025-09-widely-nasal-spray-coronavirus-infection.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Post-COVID Lung Abnormalities Commonly Improve Over Time, New Consensus Confirms
Expert consensus reveals that lung abnormalities after COVID-19 infection typically regress or stabilize over time, with severe fibrosis being rare. This guideline helps improve diagnosis and management of long COVID-related lung issues.
Substance Use Plays a Major Role in Adult Bath-Related Drownings
Recent Australian research reveals that over 50% of adult drownings in baths and hot tubs involve substance use, highlighting a vital area for public health intervention to prevent fatalities.
Media Coverage and Costs of Newly Approved Medicines: What the Media Focuses On
A Finnish study reveals how media coverage varies for new medicines, highlighting disparities unrelated to cost or prevalence, and the potential impact on public perception and health policy.
